Oliver Vit Lohnhofgaesslein 16 CH-4051 Basel Switzerland mobile: +41 79 346 38 40 olivervit@hotmail.com

Personal attributes Male Single Born 27th June 1972

Basel, Switzerland Polyvalent Analytical Persuasive Innovative Pragmatic Determined

Athletic Personal experience & achievements

New York3 yearsBachelor‘s degreeChemistry

New Jersey13 yearsCommunity CollegeHigh schoolEarly childhood

San Francisco7 yearsChildhood

Self sponsored, overland/sea travels

United KingdomPostgraduate diplomaStrategy & Innovation

Master of ScienceDrug DevelopmentHonors with distinction

Switzerland12 yearsActelion Pharmaceuticals LtdGlobal Business & Science AffairsSenior Life Cycle Project Manager

Citizenship

Switzerland Czech Republic

World Service USA Authority

Citizenship

Switzerland Czech Republic

World Service USA Authority

Education 2010 – 2011

2008 – 2009

1993 – 1996

University of Oxford Saïd Business School Postgraduate Diploma Strategy & Innovation University of London Queen Mary’s School of Medicine & Dentistry Master of Science in Drug Development Graduated with distinction New York University Bachelor’s Degree in Chemistry

Employment history Actelion Pharmaceuticals, Ltd Basel, Switzerland 2007 – 2012 Global Business & Science Affairs

Senior Life Cycle Project Manager In this position I authored protocols, developed target product profiles, co-authored clinical development plans, and conducted independent market research in parallel to grappling with moving targets and maintaining both team focus & morale. Working with no direct reports and within a matrix environment composed of members from almost every other internal department and potentially representatives of external partners, my professional function was to lead & support the Life Cycle Team as it drove programs forward through to the market respecting the limits set by the characteristics of each compound, the supporting fundamental sciences, the competitive environment, patent protection, the annual budget and Actelion's corporate vision. GB&SA was charged with the task of strategically linking apt, innovative research to both the needs of future prescribers and the continued growth of Actelion by bringing novel agents which address unmet medical needs robustly to the market in the timeliest manner. 2003 - 2006 Technical Operations

Clinical Trials Supplies Manager Upon joining Actelion, CTS management was a nascent competence and my remit extended well beyond negotiating cost efficient, timely packaging & delivery of QP released supplies globally in support of Actelion's growing number of clinical trials. In addition to liaising between the clinical teams and the 3rd party providers, I was charged with multiple tasks in building the CTS unit, e.g. writing the first SOPs, establishing global distribution networks, creating & implementing the first interdepartmental software which was used to monitor CTS stocks globally, initiate, track & trace shipments and record compliant returns & destruction prior to study closure. I was also responsible for the recruitment and training of new employees who eventually replaced the previous team under my guidance.

Almedica HPS AG Reinach, Switzerland 2001 - 2003 Client Services

Global Project Manager As my first professional experience in Switzerland this position made use of my ability to speak multiple languages, consult, pitch & negotiate contracts with potential clients in the pharmaceutical industry, identify & satisfy customer needs, understand & coordinate internally across all departments & functions to ensure both GMP compliance and the timely internal release of packaged materials within budget, and liaise with both the US head office and UK affiliate.

Products & candidates

In my role as a Senior Life Cycle Project Manager I led the multi-disciplined life cycle teams for cadazolid, olesoxime and the ponesimod follow-up compound while having provided assistance to the life cycle teams charged with the development of ponesimod, an anti-hypertensive and Zavesca® (miglustat). This cross-functional leadership role encompasses: setting & adhering to the annual budget, drafting, finalizing & adapting the integrated project plans, execution of development strategy, identification of development hurdles & market opportunities, generation, review & updating of most critical core documentation, setting & achieving project goals, matrix management, challenge & defense of corporate strategy. I have worked with multiple drug candidates & marketed products from a wide array of molecular targets employing different formulations across numerous indications in development stages: Phase I, II, III, and IV. In particular both the olesoxime and ponesimod projects were managed while in partnerships with both Trophos SA and Hoffmann-La Roche Ltd respectively.

CompoundClass

Mode of action Route ofadministration

Indication

Anti-hypertensive

L/T channel blocker oral capsule HypertensionAngina pectoris

Cadazolid Inhibition of topoisomerase & protein synthesis

oral suspension Clostridium difficile infection

Ponesimod

Sequestration of T-cells in lymph nodes and Peyer‘spatches

oral tablet

Multiple sclerosisPlaque psoriasisOther

Ponesimod f/u Auto-immune disorders

Olesoxime Mitochondrial permeability transition pore modulation

oral liquid filled capsugel

Amyotrophic Lateral SclerosisSpinal muscular atrophy

Zavesca® (miglustat)

Inhibition of glucosylceramidesynthase

oral capsule Type I GaucherNiemann-Pick Type C

Recent professional experience & group achievements

Protocols * Investigator’s brochures * Clinical development plans * Target product profiles * Competitive intelligence briefings * Business case development Alliance management Risk management plans Expert panel meetings Annual budgets New indication research * INN filings Patent filings

Pre-IND meetings o Neurology division o Dermatology division o Division of special

pathogens & transplant Clinical Trial Applications

o EU/EEA o Israel

IND filings o Neurology division o Division of special

pathogens & transplant *authorship

DISCOVERYDEVELOPMENT

MARKETING

Target selectionHTS

Lead optimisation

Candidate selection process

Preclinical testing

Safety testing Phase I

Concept testing Phase II

Full scale developmentPhase III

Submission

LaunchCommercialisation

• ••

• ••

Entry into Human

First dose inindication

First submissionFirst approval

LeadHit

• Launch key markets

Anti-hypertensive

Cadazolid

Ponesimod

Ponesimod f/u

Olesoxime

Zavesca®

Corporate deliverables inclusive of academic theses (sample non-confidential files available upon request) 2011 Actelion Pharmaceuticals Ltd Proof-of-concept protocols Target product profiles Investigator’s brochure Saϊd Business School, Oxford University Postgraduate Diploma in Strategy & Innovation “Actelion Pharmaceuticals Ltd, the Quest for a 2nd Partner” 2010 Actelion Pharmaceuticals Ltd Competitive intelligence reports Crohn’s Disease, Pharmascape Psoriasis, Pharmascape 2009 Queen Mary’s School of Medicine & Dentistry, University of London Master of Science in Drug Development “Oral MS Therapy, the Coming Revolution” Actelion Pharmaceuticals Ltd Multiple Sclerosis, Clinical Development Plan

FINAL 2011 DipSI Thesis Oliver Vit CV.pdf

Crohn's Disease Pharmascape CV.pdf

Psoriasis Pharmascape CV.pdf

FINAL 2009 MSc Thesis Oliver Vit CV.pdf

Languages

Recent conferences & trainings 2011 2010 2009

Imperial College London Immunology for Physicians & Clinicians European Committee for Treatment & Research in Multiple Sclerosis (ECTRIMS) International Society for Pharmacoeconomics & Outcomes Research (ISPOR) 12th annual conference

SpanishPortuguese

GermanFrench

English

Rudimentary

Conversational&

Written

Fluent

SpanishPortuguese

GermanFrench

English

Rudimentary

Conversational&

Written

Fluent

References Actelion Pharmaceuticals Ltd Novartis Pharma AG Bayer HealthCare Pharmaceuticals Stanford University University of London Queen Mary’s School of Medicine & Dentistry William Harvey Institute Clinical Pharmacology

Isaac Kobrin, MD (retired) Senior Vice President Chief Medical Officer itzikkob@gmail.com +41 79 372 68 66 Michael Scherz, PhD Vice President Life Cycle Leader michael.scherz@actelion.com +41 61 565 65 94 Jasper Dingemanse, PhD Vice President Head of Clinical Pharmacology jasper.dingemanse@actelion.com +41 61 565 64 63 Vaclav Sulista, PhD PU Head TRD Services vaclav.sulista@novartis.com +41 61 696 13 21 Malcolm Allison Vice President Global Team Leader PH malcolm.allison@bayer.com +49 175 309 27 50 Jed Black, MD Consulting professor Actelion Vice President (former) Therapeutic Area Head Sleep Disorders black.jed@gmail.com +1 650 464-9129 (GMT-8 h) Atholl Johnston, PhD Professor of Clinical Pharmacology Head of Postgraduate Taught Courses a.johnston@qmul.ac.uk +44 20 7882 3404

Current attestation

Additional attestations

Diplomas